Pancreatic cancer. Malignant neoplasm of pancreas
Conditions
Interventions
Intervention group: MFOLFIRINOX chemotherapy regimens (Oxalipaltin 85mg / m2 — leucovorin calcium 400mg / m2— Irinotecan 150 mg / m2 --- Fluorouracil 2400mg / m2 continous infusion over 46h are treate
cap capecitabin 625mg/m2 BID and oxaliplatin injection drug at a dosage of 65 mg / m2 from the first day of radiotherapy weekly for two weeks followed by a week of rest and then weekly for two weeks..
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients over the age of 18 to 75 years who have not previously received chemotherapy or radiotherapy in the upper abdomen, , acceptable liver, kidney, and lung function, and acceptable CBC diff the functional status of group 0 or one according to the ECOG definition. Patient with borderline and unresectable nonmetastatic pancreatic cancer
Exclusion criteria
Exclusion criteria: Serious concomitant systemic disorder Women with a positive pregnancy test or lactating Previously radiotherapy of upper abdomen Have endocrine pancreatic tumors or ampullary cancer Pathology other than pancreatic adenocarcinoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of negative surgical margin. Timepoint: the end of neoadjuvant therapy. Method of measurement: pathological evaluation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactmajid kaheh
Iran University of Medical Sciences
Outcome results
None listed